Bio‑Techne Corporation, a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

MINNEAPOLIS, Nov. 15, 2022 /PRNewswire/ -- Bio-Techne Corporation (TECH) today announced the opening of its new 52,000 square foot state-of-the-art product innovation and manufacturing facility. The ...

Minneapolis-based life sciences firm Bio-Techne Corp. on Wednesday said it’s reached a deal to buy Austin, Texas-based Asuragen for up to $320 million. Under the terms of the deal, Bio-Techne will pay ...

Bio-Techne has announced a collaboration to distribute Spear Bio’s advanced SPEAR UltraDetect immunoassays worldwide, with an initial focus on the neurology research market. This partnership allows ...

Life sciences company Bio-Techne (NASDAQ:TECH) in Q3 CY2025, with sales falling 1% year on year to $286.6 million. Its non-GAAP profit of $0.42 per share was in line with analysts’ consensus estimates ...

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The ...

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...

With a new name and a new CEO, Bio-Techne has begun an aggressive growth strategy to ensure that researchers know not only its flagship brand, R&D Systems, but the company as a whole. One year ago, ...